Real-world Efficacy, Safety, and the Impact of Spherical Equivalent on Intravitreal Anti-VEGF Therapy in Patients Affected by Myopic Choroidal Neovascularisation
Klinische Monatsblätter für Augenheilkunde · 01.07.2025 · 242 (07) · 745-751
DOI: 10.1055/a-2561-2847 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 01.07.2025. Verfasst von Peter Wolfrum und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, Germany. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Vascular Endothelial Growth Factor A, Angiogenesis Inhibitors, Myopia, Degenerative. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Purpose
To analyse real-world clinical outcomes and influence of the spherical equivalent (SE) on anti-vascular endothelial growth factor (VEGF) therapy in patients affected by myopic choroidal neovascularisation (mCNV). Patients and Methods A retrospective investigation was conducted on treatment-naïve mCNV patients receiving anti-VEGF therapy at the Department of Ophthalmology, University Medical Center Mainz, Germany, between January 2018 and March 2024. Safety, functional and morphological changes in visual acuity (VA), central retinal thickness (CRT), and central retinal volume (CRV) were evaluated over a two-year period. Further, we analysed how baseline VA and CRT relate to itʼs final outcome measures. Finally, a subgroup analysis assessed the impact of SE above and below − 10 D.
Results
Significant improvements in VA, CRT, and CRV were observed. VA improved from 0.5 ± 0.27 logMAR to 0.38 ± 0.31 logMAR (p = 0.005) at 6 months and remained stable at 2 years. CRT and CRV decreased from 344.4 ± 115.0 µm to 284.2 ± 45.2 µm (p < 0.001) and 0.27 ± 0.09 mm³ to 0.22 ± 0.04 mm³ (p < 0.001), respectively, four weeks after the initial injection, with stability maintained thereafter. Baseline VA correlated strongly with final VA, whereas CRT did not. No adverse events were reported. The subgroup analysis showed no significant outcome differences based on SE.
Conclusion
Anti-VEGF therapy in mCNV patients proved to be safe and effective in our study with sustained improvement in functional and anatomical measures. Baseline VA strongly predicted final VA, whereas baseline and final CRT showed no association. No differences in treatment outcomes were observed as based on a varying SE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, Germany.
Zitieren
APA
Wolfrum, P., Voigt, A. M., Lorenz, K., Stoffelns, B. M., & Korb, C. A. (2025). Real-world Efficacy, Safety, and the Impact of Spherical Equivalent on Intravitreal Anti-VEGF Therapy in Patients Affected by Myopic Choroidal Neovascularisation. Klinische Monatsblätter für Augenheilkunde, 242(07), 745-751. https://doi.org/10.1055/a-2561-2847
Vancouver
Wolfrum P, Voigt AM, Lorenz K, Stoffelns BM, Korb CA. Real-world Efficacy, Safety, and the Impact of Spherical Equivalent on Intravitreal Anti-VEGF Therapy in Patients Affected by Myopic Choroidal Neovascularisation. Klinische Monatsblätter für Augenheilkunde. 2025;242(07):745-751. doi:10.1055/a-2561-2847
BibTeX
@article{Wolfrum2025,
author = {Wolfrum, Peter and Voigt, Anna Maria and Lorenz, Katrin and Stoffelns, Bernhard M and Korb, Christina A},
title = {Real-world Efficacy, Safety, and the Impact of Spherical Equivalent on Intravitreal Anti-VEGF Therapy in Patients Affected by Myopic Choroidal Neovascularisation},
journal = {Klinische Monatsblätter für Augenheilkunde},
year = {2025},
volume = {242},
number = {07},
pages = {745--751},
doi = {10.1055/a-2561-2847}
}
EUVIMED